Comparative Pharmacology
Head-to-head clinical analysis: ARIKAYCE KIT versus ETHAMBUTOL HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARIKAYCE KIT versus ETHAMBUTOL HYDROCHLORIDE.
ARIKAYCE KIT vs ETHAMBUTOL HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit of susceptible bacteria, causing misreading of mRNA and inhibiting protein synthesis.
Inhibits arabinosyl transferase (emb) involved in cell wall synthesis of mycobacteria, specifically inhibiting polymerization of arabinose into arabinan, a component of arabinogalactan.
590 mg (contents of one kit) administered as inhalation via the Lamira Nebulizer System once daily.
15 mg/kg orally once daily (range 15-25 mg/kg); typically 800-1600 mg daily.
None Documented
None Documented
The terminal elimination half-life of amikacin from plasma is approximately 2-3 hours in patients with normal renal function. In the liposomal formulation (ARIKAYCE), after inhalation, the half-life in epithelial lining fluid is prolonged, with a terminal half-life of approximately 23 hours. Clinical context: accumulation may occur with renal impairment.
3–4 hours in normal renal function; prolonged to 7–15 hours in moderate renal impairment and up to 30 hours in severe renal impairment; clinical context: requires dosing adjustment when creatinine clearance <30 mL/min.
Amikacin is primarily eliminated unchanged by glomerular filtration; renal excretion accounts for approximately 94-98% of the dose within 24 hours. Biliary/fecal elimination is minimal (<1%).
Renal: ~80% as unchanged drug and metabolites via glomerular filtration and tubular secretion; fecal: ~15%; biliary: <2%.
Category C
Category A/B
Antimycobacterial
Antimycobacterial